Jolley Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Jolley Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1	Closed	–	–	106
2018 Q2	$0	Hold	1	–	–	﹤0.01%	177
2018 Q1	$0	Hold	1	–	–	﹤0.01%	186
2017 Q4	$0	Hold	1	–	–	﹤0.01%	179
2017 Q3	$0	Hold	1	–	–	﹤0.01%	181
2017 Q2	$0	Hold	1	–	–	﹤0.01%	167
2017 Q1	$0	Hold	1	–	–	﹤0.01%	153
2016 Q4	$0	Hold	1	–	–	﹤0.01%	155
2016 Q3	$0	Hold	1	–	–	﹤0.01%	150
2016 Q2	$0	Hold	1	–	–	﹤0.01%	149
2016 Q1	$0	Hold	1	–	–	﹤0.01%	143
2015 Q4	$0	Hold	1	–	–	﹤0.01%	120
2015 Q3	$0	Hold	1	–	–	﹤0.01%	115
2015 Q2	$1K	Hold	1	–	–	﹤0.01%	117
2015 Q1	$1K	Hold	1	–	–	﹤0.01%	118
2014 Q4	$1K	Hold	1	–	–	﹤0.01%	121
2014 Q3	$1K	Hold	1	–	–	﹤0.01%	117
2014 Q2	$2K	Hold	1	–	–	﹤0.01%	124
2014 Q1	$2K	Hold	1	–	–	﹤0.01%	119
2013 Q4	$2K	Hold	1	–	–	﹤0.01%	123
2013 Q3	$3K	Hold	1	–	–	﹤0.01%	117
2013 Q2	$2K	Buy	+1	New	+$3.81K	﹤0.01%	116

Other funds holding GYRE

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Jolley Asset Management's GYRE Position: Q3 2018 in Review

Jolley Asset Management sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 1 share.

Jolley Asset Management first reported a position in GYRE in Q2 2013 and held it in 21 quarters. The position peaked at $3K in Q3 2013. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

Jolley Asset Management reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
Jolley Asset Management sold 1 Gyre Therapeutics share in Q3 2018.
Jolley Asset Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 21 quarters.
Jolley Asset Management's Gyre Therapeutics position peaked at $3K in Q3 2013.
70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Jolley Asset Management's 13F filing for Q3 2018, filed 18 Oct 2018.